{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:30:01Z","timestamp":1791063001539,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI071651"],"award-info":[{"award-number":["AI071651"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["UL1 RR024999"],"award-info":[{"award-number":["UL1 RR024999"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000882","name":"Brain Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000964","name":"Arthritis National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001218","name":"Lupus Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 AI083790"],"award-info":[{"award-number":["K08 AI083790"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK42086"],"award-info":[{"award-number":["P30 DK42086"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.jns.2011.09.032","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T15:26:42Z","timestamp":1319815602000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis"],"prefix":"10.1016","volume":"313","author":[{"given":"Xuan","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P.","family":"Reder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounica","family":"Yanamandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addie","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly S.","family":"Franek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy B.","family":"Niewold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Reder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2011.09.032_bb0005","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2011.09.032_bb0010","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.09.032_bb0015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2011.09.032_bb0020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(03)12784-5","article-title":"Neuromyelitis optica: what it is and what it might be","volume":"361","author":"Weinshenker","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2011.09.032_bb0025","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.09.032_bb0030","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/rheumatology\/38.2.191","article-title":"The association of optic neuropathy with transverse myelitis in systemic lupus erythematosus","volume":"38","author":"Giorgi","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.jns.2011.09.032_bb0035","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/1352458508088941","article-title":"Minor salivary gland inflammation in Devic's disease and longitudinally extensive myelitis","volume":"14","author":"Javed","year":"2008","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2011.09.032_bb0040","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1212\/WNL.49.3.857","article-title":"Frequency and significance of antinuclear antibodies in multiple sclerosis","volume":"49","author":"Collard","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.09.032_bb0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2005.08.011","article-title":"Therapeutic role of beta-interferons in multiple sclerosis","volume":"110","author":"Javed","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jns.2011.09.032_bb0050","series-title":"Handbook of clinical neurology: demyelinating diseases","first-page":"337","article-title":"Immunology of multiple sclerosis","author":"Reder","year":"1985"},{"key":"10.1016\/j.jns.2011.09.032_bb0055","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jns.2011.09.032_bb0060","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jns.2011.09.032_bb0065","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/art.23613","article-title":"Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients","volume":"58","author":"Niewold","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jns.2011.09.032_bb0070","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","article-title":"Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj\u00f6gren's syndrome","volume":"103","author":"Gottenberg","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jns.2011.09.032_bb0075","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/gene.2009.20","article-title":"Peripheral blood gene expression profiling in Sj\u00f6gren's syndrome","volume":"10","author":"Emamian","year":"2009","journal-title":"Genes Immun"},{"key":"10.1016\/j.jns.2011.09.032_bb0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/0961203308093550","article-title":"Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis","volume":"18","author":"Bonaci-Nikolic","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.jns.2011.09.032_bb0085","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/RHU.0b013e3181775e80","article-title":"Severe systemic lupus erythematosus induced by antiviral treatment for hepatitis C","volume":"14","author":"Ho","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jns.2011.09.032_bb0090","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/brain\/awn077","article-title":"Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity","volume":"131","author":"Krumbholz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jns.2011.09.032_bb0095","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2011.09.032_bb0100","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN-\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.09.032_bb0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000227277","article-title":"Interferon-\u03b2 (1b) treatment in neuromyelitis optica","volume":"62","author":"Tanaka","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jns.2011.09.032_bb0110","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2011.09.032_bb0115","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.rdc.2009.12.008","article-title":"Interferon-alpha: a therapeutic target in systemic lupus erythematosus","volume":"36","author":"Crow","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jns.2011.09.032_bb0120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-0404.1998.tb05966.x","article-title":"Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients","volume":"97","author":"Wandinger","year":"1998","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jns.2011.09.032_bb0125","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/107999099313901","article-title":"Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-alpha and IFN-beta","volume":"19","author":"Jabs","year":"1999","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jns.2011.09.032_bb0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0165-5728(02)00182-0","article-title":"Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1","volume":"129","author":"Feng","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2011.09.032_bb0135","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun"},{"key":"10.1016\/j.jns.2011.09.032_bb0140","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nm.2110","article-title":"T helper type 1 and 17 cells determine efficacy of interferon-\u03b2 in multiple sclerosis and experimental encephalomyelitis","volume":"16","author":"Axtell","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jns.2011.09.032_bb0145","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1212\/WNL.0b013e3181f6c556","article-title":"Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS","volume":"75","author":"van der Voort","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.09.032_bb0225","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1093\/brain\/awp228","article-title":"A type I interferon signature in monocytes is associated with poor response to interferon-\u03b2 in multiple sclerosis","volume":"132","author":"Comabella","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.jns.2011.09.032_bb0160","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1212\/WNL.0b013e3181f6466f","article-title":"MxA: a biomarker for predicting multiple sclerosis disease activity","volume":"75","author":"Reder","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.09.032_bb0165","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jneuroim.2007.12.007","article-title":"IFN-\u03b2-regulated genes show abnormal expression in therapy-naive relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein\u2013protein interactions","volume":"195","author":"Yamaguchi","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2011.09.032_bb0170","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/jir.2007.0131","article-title":"IFN-\u03b2-1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression","volume":"28","author":"Reder","year":"2008","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jns.2011.09.032_bb0175","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jns.2011.09.032_bb0180","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.gene.6364408","article-title":"High serum IFN-\u03b1 activity is a heritable risk factor for systemic lupus erythematosus","volume":"8","author":"Niewold","year":"2007","journal-title":"Genes Immun"},{"key":"10.1016\/j.jns.2011.09.032_bb0185","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","article-title":"Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy","volume":"60","author":"Niewold","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jns.2011.09.032_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren's syndrome","volume":"109","author":"Groom","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jns.2011.09.032_bb0230","unstructured":"Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res. Epub 02-22-11."},{"key":"10.1016\/j.jns.2011.09.032_bb0200","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/1352458510380416","article-title":"Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population","volume":"16","author":"Vaknin-Dembinsky","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2011.09.032_bb0205","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/jir.2010.0098","article-title":"Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta","volume":"30","author":"Gilli","year":"2010","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jns.2011.09.032_bb0210","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2010.10.033","article-title":"Gene expression in IFN \u03b2 signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients","volume":"230","author":"Oliver-Martos","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.jns.2011.09.032_bb0215","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1089\/10799900252952280","article-title":"Mechanisms for regulation of cellular responsiveness to human IFN-beta1a","volume":"22","author":"Dupont","year":"2002","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jns.2011.09.032_bb0220","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/1097-0258(20000715)19:13<1793::AID-SIM482>3.0.CO;2-Q","article-title":"Modelling covariance structure in the analysis of repeated measures data","volume":"19","author":"Littell","year":"2000","journal-title":"Stat Med"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11005946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11005946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:42:43Z","timestamp":1758382963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X11005946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":43,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0022510X11005946"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2011.09.032","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2011.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}